Access the full text.
Sign up today, get DeepDyve free for 14 days.
F. Petitet, B. Jeantaud, M. Reibaud, A. Imperato, M. Dubroeucq (1998)
Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of delta9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors.Life sciences, 63 1
Yung‐chi Cheng, W. Prusoff (1973)
Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.Biochemical pharmacology, 22 23
V. Showalter, D. Compton, Billy Martin, M. Abood (1996)
Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands.The Journal of pharmacology and experimental therapeutics, 278 3
A. Corbett, G. Henderson, A. Mcknight, S. Paterson (2006)
75 years of opioid research: the exciting but vain quest for the Holy GrailBritish Journal of Pharmacology, 147
Cannabinoid antagonism by cannabidiol A Thomas et al
Juha Savinainen, S. Saario, R. Niemi, T. Järvinen, J. Laitinen (2003)
An optimized approach to study endocannabinoid signaling: evidence against constitutive activity of rat brain adenosine A1 and cannabinoid CB1 receptorsBritish Journal of Pharmacology, 140
M. Rhee, Sang-keun Kim (2002)
SR144528 as inverse agonist of CB2 cannabinoid receptor.Journal of veterinary science, 3 3
T. Bisogno, L. Hanuš, L. Petrocellis, S. Tchilibon, D. Ponde, I. Brandi, A. Moriello, John Davis, R. Mechoulam, V. Marzo (2001)
Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamideBritish Journal of Pharmacology, 134
J Pharmacol Exp Ther
E. Carrier, J. Auchampach, C. Hillard (2006)
Inhibition of an equilibrative nucleoside transporter by cannabidiol: A mechanism of cannabinoid immunosuppression, 103
R. Ross, Heather Brockie, L. Stevenson, Vicki Murphy, Fiona Templeton, A. Makriyannis, R. Pertwee (1999)
Agonist‐inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630British Journal of Pharmacology, 126
C. Mignat, Uta Wille, Albrecht Ziegler (1995)
Affinity profiles of morphine, codeine, dihydrocodeine and their glucuronides at opioid receptor subtypes.Life sciences, 56 10
Pertwee (1999)
10.2174/0929867306666220401124036Curr Med Chem, 6
M. Elsohly, D. Slade (2005)
Chemical constituents of marijuana: the complex mixture of natural cannabinoids.Life sciences, 78 5
C. Breivogel, G. Griffin, V. Marzo, B. Martin (2001)
Evidence for a new G protein-coupled cannabinoid receptor in mouse brain.Molecular pharmacology, 60 1
R. Pertwee (2005)
Inverse agonism and neutral antagonism at cannabinoid CB1 receptors.Life sciences, 76 12
B. Thomas, A. Gilliam, D. Burch, M. Roche, H. Seltzman (1998)
Comparative receptor binding analyses of cannabinoid agonists and antagonists.The Journal of pharmacology and experimental therapeutics, 285 1
Showalter (1996)
10.1016/j.neuropharm.2005.11.008J Pharmacol Exp Ther, 278
P. Leff (1995)
The two-state model of receptor activation.Trends in pharmacological sciences, 16 3
Marielle Portier, M. Rinaldi-Carmona, Florence Pecceu, Thérèse Combes, C. Poinot-Chazel, B. Calandra, Francis Barth, G. Fur, Pierre Casellas (1999)
SR 144528, an antagonist for the peripheral cannabinoid receptor that behaves as an inverse agonist.The Journal of pharmacology and experimental therapeutics, 288 2
M. Kathmann, K. Flau, A. Redmer, C. Tränkle, E. Schlicker (2006)
Cannabidiol is an allosteric modulator at mu- and delta-opioid receptorsNaunyn-Schmiedeberg's Archives of Pharmacology, 372
R. Pertwee, A. Thomas, L. Stevenson, Y. Maor, R. Mechoulam (2005)
Evidence that (−)-7-hydroxy-4′-dimethylheptyl-cannabidiol activates a non-CB1, non-CB2, non-TRPV1 target in the mouse vas deferensNeuropharmacology, 48
R. Pertwee, G. Griffin, J. Lainton, J. Huffman (1995)
Pharmacological characterization of three novel cannabinoid receptor agonists in the mouse isolated vas deferens.European journal of pharmacology, 284 3
(2006)
Cannabidiol is an inverse agonist and exhibits unexpectedly high potency as an antagonist at mouse brain CB 1 and human CB 2 receptors
C. Lunn, Jay Fine, A. Rojas-Triana, James Jackson, Xuedong Fan, Ted Kung, W. Gonsiorek, Martin Schwarz, Brian Lavey, Joseph Kozlowski, Satwant Narula, Daniel Lundell, R. Hipkin, L. Bober (2006)
A Novel Cannabinoid Peripheral Cannabinoid Receptor-Selective Inverse Agonist Blocks Leukocyte Recruitment in VivoJournal of Pharmacology and Experimental Therapeutics, 316
R. Pertwee, R. Ross, Susan Craib, A. Thomas (2002)
(-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens.European journal of pharmacology, 456 1-3
M. Bouaboula, Nathalie Desnoyer, P. Carayon, T. Combes, P. Casellas (1999)
Gi protein modulation induced by a selective inverse agonist for the peripheral cannabinoid receptor CB2: implication for intracellular signalization cross-regulation.Molecular pharmacology, 55 3
A. Thomas, R. Ross, B. Saha, A. Mahadevan, R. Razdan, R. Pertwee (2004)
6"-Azidohex-2"-yne-cannabidiol: a potential neutral, competitive cannabinoid CB1 receptor antagonist.European journal of pharmacology, 487 1-3
A. Thomas, L. Stevenson, K. Wease, Martin Price, G. Baillie, R. Ross, R. Pertwee (2005)
Evidence that the plant cannabinoid Δ9‐tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonistBritish Journal of Pharmacology, 146
R. Pertwee (1999)
Pharmacology of cannabinoid receptor ligands.Current medicinal chemistry, 6 8
Background and purpose: A nonpsychoactive constituent of the cannabis plant, cannabidiol has been demonstrated to have low affinity for both cannabinoid CB1 and CB2 receptors. We have shown previously that cannabidiol can enhance electrically evoked contractions of the mouse vas deferens, suggestive of inverse agonism. We have also shown that cannabidiol can antagonize cannabinoid receptor agonists in this tissue with a greater potency than we would expect from its poor affinity for cannabinoid receptors. This study aimed to investigate whether these properties of cannabidiol extend to CB1 receptors expressed in mouse brain and to human CB2 receptors that have been transfected into CHO cells. Experimental approach: The (35S)GTPγS binding assay was used to determine both the efficacy of cannabidiol and the ability of cannabidiol to antagonize cannabinoid receptor agonists (CP55940 and R‐(+)‐WIN55212) at the mouse CB1 and the human CB2 receptor. Key results: This paper reports firstly that cannabidiol displays inverse agonism at the human CB2 receptor. Secondly, we demonstrate that cannabidiol is a high potency antagonist of cannabinoid receptor agonists in mouse brain and in membranes from CHO cells transfected with human CB2 receptors. Conclusions and implications: This study has provided the first evidence that cannabidiol can display CB2 receptor inverse agonism, an action that appears to be responsible for its antagonism of CP55940 at the human CB2 receptor. The ability of cannabidiol to behave as a CB2 receptor inverse agonist may contribute to its documented anti‐inflammatory properties. British Journal of Pharmacology (2007) 150, 613–623. doi:10.1038/sj.bjp.0707133
British Journal of Pharmacology – Wiley
Published: Mar 1, 2007
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.